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ABSTRACT 
Background: Dual antiplatelet therapy with acetylsalicylic acid (ASA) and the 
adenosine diphosphate (ADP)-receptor antagonist ticagrelor increases the risk of 
bleeding complications during cardiac surgery. The overall aim of this thesis was to 
identify and evaluate current and potential methods to reduce and prevent bleeding 
complications in patients with ongoing antiplatelet therapy. 
Methods: In Study I, three types of platelet concentrates were sampled on day 1, 4 
and 7 after donation. In Study II, adrenaline and platelet concentrate were added to 
blood samples from acute coronary syndrome patients on ASA and ticagrelor. In 
Study III, blood samples from healthy volunteers were collected after ticagrelor, 
adrenaline and metoprolol administration. In Study IV, blood samples were collected 
before and after anesthesia induction from cardiac surgery patients randomized to 
standard treatment or maintenance of preoperative mean arterial pressure using 
noradrenaline. Platelet aggregation was assessed with impedance aggregometry 
(Studies I‒IV) while platelet activation was assessed with flow cytometry (Studies I‒
III). Clot formation was assessed with thromboelastometry (Studies III and IV). 
Results: Platelets in interim platelet unit (IPU) concentrates maintained a lower 
activation state and better aggregation response to the end of storage compared to 
buffy-coat concentrates (I). More platelets in IPU concentrates were activated and 
had a lower aggregation response throughout storage compared to apheresis 
concentrates (I). Adrenaline, but not platelet concentrate, improved ADP-induced 
platelet aggregation and activation in the presence of ticagrelor in vitro (II). 
Adrenaline infusion improved ADP-induced platelet aggregation, activation and clot 
formation in healthy volunteers treated with ticagrelor (III). Intraoperative 
noradrenaline infusion improved ADP-induced platelet aggregation and clot 
formation in cardiac surgery patients (IV). 
 Conclusions: The quality of IPU concentrates is at least comparable to buffy-coat 
concentrates. Adrenergic agents improve platelet reactivity and may thus potentially 
be used to prevent excessive bleeding during surgery in patients with ongoing 
antiplatelet therapy. 
Keywords: Platelet concentrate, adrenaline, noradrenaline, ticagrelor, platelet 
aggregation, platelet activation  
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SAMMANFATTNING PÅ SVENSKA 
Allvarlig blödning under och efter hjärtoperationer är en farlig men relativt 
vanlig händelse som påtagligt ökar risken för död och andra allvarliga 
komplikationer. Orsaken till blödning kan exempelvis vara att patienten har 
ätit ett eller flera läkemedel som hämmar trombocyters (blodplättars) förmåga 
att aktiveras och aggregera (klumpa ihop sig med varandra), såsom 
acetylsalicylsyra ensamt eller i kombination med ticagrelor, tätt inpå 
operationen. Helst vill man att patienten ska ha slutat äta ticagrelor flera 
dagar innan operation men ibland går det inte p.g.a. patientens tillstånd. 
Trombocythämmande läkemedel används vid behandling av akut koronart 
syndrom (AKS). AKS uppstår då blodproppar förhindrar blodflödet genom 
artärerna i hjärtat vilket kan leda till hjärtinfarkt eller hjärtstopp. För att 
förhindra bildandet av blodproppar behandlas AKS-patienter med 
acetylsalicylsyra och ticagrelor vilket är effektivt men tyvärr ökar risken för 
blödning om patienter behöver opereras akut. Idag ges ofta transfusioner av 
trombocytkoncentrat från blodgivare för att stoppa blödningarna. 
Trombocytkoncentraten kan förvaras i maximalt 7 dagar efter blodgivning 
men trombocyternas kvalitet försämras tyvärr under förvaringstiden. Det har 
tidigare visats att trombocyttransfusioner förbättrar den signalväg i 
trombocyten som acetylsalicylsyra hämmar men att de endast har en liten 
effekt på den ticagrelor-hämmade signalvägen. När patienter vars 
trombocyter är hämmade av ticagrelor hjärtopereras så är risken för allvarlig 
blödning kopplad till trombocyters förmåga att aggregera via den ticagrelor-
hämmade vägen. Målet med denna avhandling var att utvärdera nuvarande 
samt nya strategier för behandling och förebyggande av blödning hos 
patienter behandlade med trombocythämmare. 
I delarbetena mättes trombocyternas förmåga att bilda koagel (aggregation) 
med impedansaggregometri. Med denna metod mäts impedansen (förändring 
i motstånd) mellan två elektroder i en testcell. Då trombocyter aggregerar på 
elektroderna ökar impedansen vilket mäts i instrumentet och man får ett mått 
på trombocyteras aggregationsförmåga. Trombocyternas aktiveringsgrad och 
förmåga att aktiveras mättes med flödescytometri. I denna metod används 
antikroppar (en typ av proteiner) som endast binder till aktiverade 
trombocyter vilket kan mätas i instrumentet när trombocyterna utsätts för 
laserstrålar. Instrumentet räknar ett antal trombocyter och resultatet visar hur 
stor procent av trombocyterna som är aktiverade. Slutligen mättes 
koagelbildning (levringsförmåga) med tromboelastometri där en roterande 
pinne i en testcell hindras i sin rörelse när ett koagel bildas. Parametrar som 
 man kan få ut är exempelvis tiden det tar för koagelbildning och koaglets 
stabilitet. 
I första delarbetet jämfördes kvaliteten av olika trombocytkoncentrat. De nya 
interim platelet unit (IPU)-koncentraten jämfördes med buffy-coat och 
aferes-trombocytkoncentrat under förvaringstiden avseende metaboliska 
parameterar samt trombocytfunktion (trombocyternas aktiveringsgrad och 
aggregationsförmåga). Prover togs 1, 4 och 7 dagar efter givning.  Resultaten 
visade att trombocyter i IPU-koncentraten hade en högre aktiveringsgrad och 
sämre aggregationsförmåga än buffy-coat koncentrat i början av förvaringen 
men behöll en bättre trombocytfunktion vid slutet av förvaringstiden. Aferes-
trombocytkoncentraten hade en bättre trombocytfunktion under hela 
förvaringstiden jämfört med IPU-koncentraten.  
I andra delarbetet tillsattes adrenalin och trombocytkoncentrat till blodprover 
från AKS-patienter med pågående behandling med acetylsalicylsyra och 
ticagrelor. För att utvärdera effekten på trombocytfunktionen mättes 
trombocyternas förmåga att aktiveras och aggregera. Resultaten visade att 
adrenalin förbättrade både den ticagrelor-hämmade och acetylsalicylsyra-
hämmade signalvägen (aggregation och aktivering). Trombocytkoncentrat 
hade ingen effekt på den ticagrelor-hämmade vägen men förbättrade den 
acetylsalicylsyra-hämmade vägen (aggregation). En kombination av 
adrenalin och trombocytkoncentrat förbättrade aggregation via båda 
aktiveringsvägarna. 
I det tredje delarbetet gavs adrenalin i form av en infusion till friska frivilliga. 
Prover togs efter att ticagrelor, adrenalin samt en betablockerare givits. Vi 
utvärderade effekten på trombocytfunktion (aktivering och aggregation) och 
koagelbildning. Resultaten visade att adrenalininfusion förbättrade den 
ticagrelor-hämmade signalvägen (aggregation och aktivering) och även 
signalvägen som hämmas av acetylsalicylsyra (aggregation). Dessutom 
förbättrades koagelbildningen. Att ge en betablockerare tillsammans med 
adrenalin påverkade inte adrenalinets effekt på trombocytaggregationen 
negativt.   
I fjärde delarbetet fick patienter som genomgick hjärtoperation antingen 
sedvanlig behandling eller noradrenalininfusion för att behålla samma 
blodtryck som innan sövning. Prover togs innan samt 50 minuter efter 
patienten sövts. Noradrenalin förbättrade både signalvägen som hämmas av 
ticagrelor och den acetylsalicylsyra-hämmade signalvägen, jämfört med 
patienter som fick sedvanlig behandling. Dessutom förbättrades 
koagelbildningen.  
För att sammanfatta, kvaliteten av IPU-koncentrat är åtminstone lika bra som 
buffy-coat koncentrat. Adrenalin och noradrenalin skulle kunna användas för 
att förbättra trombocytfunktion och koagelbildning hos patienter behandlade 
med trombocythämmare i syfte att förebygga allvarliga blödningar.
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1 INTRODUCTION 
1.1 Hemostasis 
When a vascular injury occurs, the human body responds to stop the 
bleeding. This response is named hemostasis. Hemostatic mechanisms 
include vasoconstriction of the wounded vessels to reduce blood flow as well 
as formation of a platelet plug and coagulation of the blood to reduce blood 
loss through the damaged vessel wall [1].  
Primary hemostasis 
The primary hemostasis includes vasoconstriction and platelet plug 
formation. Platelets are cell fragments derived from the cytoplasm of 
megakaryocytes [2] with a life-span of up to 10 days in circulation [3]. 
Platelets contain mitochondria, α- and dense granules but no nucleus. The α 
granules contain proteins needed for platelet adhesion and repair of the vessel 
wall, such as the membrane-bound protein P-selectin (CD62p) and the 
soluble proteins von Willebrand factor (vWF) and fibrinogen needed for 
platelet-platelet and platelet-endothelial interactions [4]. They also contain 
prothrombin and the coagulation factors V, IX and XIII. Dense granule 
content includes adenosine diphosphate (ADP), calcium ions, serotonin and 
the membrane-bound protein CD63. Upon platelet activation, the membrane-
bound proteins will be expressed on the platelet surface membrane while 
soluble mediators will be secreted into the extracellular environment [4]. 
Platelets can become activated by different stimuli as they express a number 
of different receptors on their surface (Figure 1). A damaged vessel wall 
exposes collagen/vWF complexes which circulating platelets can bind to by 
first rolling and then adhering to the endothelial surface. When the platelet 
has bound and become activated by collagen, the granule content is released 
which will recruit more platelets to the damaged area in order to form a 
platelet plug. Release of thrombin, ADP and thromboxane A2 (TXA2) will 
activate the recruited platelets. For bridging between platelets, the activated 
fibrinogen receptor glycoprotein IIb/IIIa (GP IIb/IIIa) enables binding of 
fibrinogen, fibrin and vWF and allows for platelet-platelet adhesion. By 
adhering to each other, the platelets will form a platelet plug to seal the 
wounded area and reduce blood loss [5]. 
Platelet activation and aggregation: Clinical and experimental studies 
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Secondary hemostasis 
To stabilize the formed platelet plug, the secondary hemostasis occurs which 
is the formation of a stabilized fibrin-crosslinked clot (Figure 2). This process 
depends on coagulation factors that will activate each other forming a 
cascade (Figure 3).  
In the initiation phase, released tissue factor from, for instance, damaged 
endothelial cells activates factor VII in the blood. This complex further 
activates factor IX and X. Factor V can both be released by platelets and be 
bound to the platelet membrane. The activated factor X will form a complex 
with factor V on the platelet membrane and is together with calcium ions 
known as the prothrombin activator. Activated factor X in this complex will 
convert prothrombin to thrombin [1, 6]. 
Figure 1. Schematic illustration of a platelet with a number of receptors and activation
pathways. ADP: adenosine diphosphate; COX-1: cyclooxygenase-1; GP: glycoprotein; 
PAR: protease-activated receptor; TP: thromboxane receptor; TXA2: thromboxane A2; 
vWF: von Willebrand factor.      
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In the amplification phase, the generated thrombin from the initiation phase 
will activate platelets and also activate factors V, VIII and XI [6]. Activated 
platelets expose a negatively charged procoagulant surface on which 
complexes of coagulation factors can form rapidly. This localizes the 
coagulation to the site of injury. Activated factor IX, formed in the initiation 
phase, forms a complex with activated factor VIII on the membrane and 
activated factor X binds activated factor V which results in a fast and large 
thrombin generation [6]. Thrombin can cleave fibrinogen to fibrin and 
activate factor XIII which can then crosslink the fibrin. The fibrin will 
stabilize the original platelet plug to form a stabilized clot together with 
adhesive proteins to keep the clot attached to the damaged area (Figure 2) [1].  
Different mechanisms for controlling the clot formation exist. These restrict 
clotting from occurring when not needed as well as dissolve the clot when the 
site of injury is repaired. There are also soluble factors that can bind 
components of the coagulation to inactivate them. For instance, 
heparin/antithrombin III binds to thrombin and inhibits its action. Endothelial 
cells also exhibit anticoagulant properties. The intact endothelium expresses 
heparan sulfate and secrete soluble factors such as prostaglandin I2 and nitric 
oxid to prevent platelet adhesion and aggregation [1, 7]. Thrombomodulin is 
expressed on the membrane of endothelial cells and forms a complex with 
thrombin to inhibit its action. In addition, this complex activates protein C 
which inactivates coagulation factors V and VIII (Figure 3). To dissolve the 
clot when the injured area has been repaired, fibrinolysis will occur. 
Fibrinolysis is the cleavage of the fibrin threads and occurs when endothelial 
cells secrete tissue plasminogen activator which will catalyze the formation 
Figure 2. Schematic illustration of platelets derived from cytoplasm
of megakaryocyte (left) and platelets entrapped in a fibrin mesh located to
the injured area of a blood vessel (right). © 1999-2018, Rice University.
OpenStax CNX. https://cnx.org/contents/GFy_h8cu@10.53:_XipwKIy@4/
Components-of-the-Blood Public domain. 
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of plasmin from plasminogen localized in the clot. Plasmin will cleave the 
fibrin threads to dissolve the clot [1]. 
1.2 Coronary artery bypass grafting 
In 1896, Ludwig Rehn performed the first successful surgery on the heart 
when he sutured a 1.5 cm stab wound [8]. At the end of World War II, many 
operations removing foreign objects from in or near the heart of soldiers were 
performed [9]. In the 1950s, strategies to interrupt the blood flow to the heart 
were introduced in order to perform surgery in the heart. John Gibbon 
developed a mechanical heart and lung machine which was an extracorporeal 
circuit that maintained circulation and oxygenation of the patient’s blood 
[10]. In 1953, he performed the first successful open heart surgery with total 
cardiopulmonary bypass (CPB) in a 18-year old patient with a large atrial 
septal defect [10]. The heart and lung machine was further developed and 
solutions for priming the extracorporeal system were introduced [11]. After 
the introduction of coronary angiography for the visualization of arteries and 
possible blockage, techniques for revascularization in patients with coronary 
artery disease were developed. In the late 1960s, coronary artery bypass 
grafting (CABG) which bypasses the blockage using saphenous vein was first 
introduced [11] (Figure 4).  
Figure 3. Illustration of the classic version of the coagulation
cascade. TFPI: Tissue factor pathway inhibitor. https://commons.
wikimedia.org/wiki/File:Coagulation_full.svg Public domain. 
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In Sweden, 5,809 cardiac operations 
were performed in 2017 and 3,285 
operations were CABG alone or 
combined with other cardiac 
interventions. The thirty-day 
mortality rate was 1.8% [12]. In a 
population-based study from 
Sweden, the mortality rate in patients 
that had survived the first 30 days 
after CABG alone (in the time-period 
௅ was approximately 1% 
in patients DJHG௅\HDUV and 2% 
in patients that were 55 years or older 
[13]. In addition, the older patient 
group had a lower mortality risk than 
the general population (age- and 
gender-matched) [13]. 
Bleeding in cardiac surgery 
During cardiac surgery, there is a risk of bleeding complications which is 
associated with high morbidity and mortality rates [14]. In a study on adult 
cardiac surgery patients, severe bleeding was associated with an eight-fold 
increase in perioperative deaths, after adjustment for other factors influencing 
mortality [14]. Furthermore, CABG patients operated after an episode of 
acute coronary syndrome (ACS) and suffering from severe bleeding had a 14 
times higher unadjusted 30-day mortality compared to patients without 
bleeding complications (9.9% vs 0.7%) [15]. In approximately 5% of all 
cardiac operations, the patient needs to undergo reoperation due to bleeding 
[12] which increases the risk of perioperative renal failure, stroke and 
mortality significantly [16, 17]. The postoperative mortality rate was doubled 
in patients undergoing reoperation due to bleeding after adjustment for other 
factors associated with death [16]. There are different factors that may 
contribute to the bleeding including hemodilution by the priming solutions in 
the CPB circuit, hypothermia, use of high dose heparin, and the use of CPB, 
which impairs platelet function, activates the coagulation cascade, and 
increases inflammation and fibrinolysis as the blood becomes exposed to 
foreign surfaces [18, 19]. Another factor that affects bleeding is ongoing or 
recently discontinued treatment with anticoagulant or antiplatelet medication. 
Figure 4. Schematic illustration of a heart
and coronary artery bypass grafts done by
Patrick J. Lynch, medical illustrator; C. Carl
Jaffe,  MD, cardiologist. https://commons.
wikimedia.org/wiki/File:Heart_saphenous_co
ronary_grafts.jpg Public domain. 
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1.3 Antiplatelet medication 
Antiplatelet medication is used to prevent thrombotic events in patients with 
ACS by inhibition of platelet activation and aggregation pathways. Dual 
antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and an ADP-
receptor (P2Y12) antagonist such as clopidogrel or ticagrelor is more effective 
in reducing thrombotic events than monotherapy with ASA only, but also 
increases the risk of perioperative bleeding complications [20-22]. 
Acetylsalicylic acid 
ASA (Figure 5) was first marketed in 1899 as aspirin and used to relieve 
pain, fever and inflammation. It was later in the 1980s discovered that ASA 
also had an effect on platelets [23]. ASA irreversibly inhibits 
cyclooxygenase-1 (COX-1) and the inhibition will therefore last for the 
whole life-span of the platelet. COX-1 is needed for conversion of 
arachidonic acid (AA) to prostaglandin H2 to ultimately produce TXA2 
(Figure 6) [24-26]. TXA2 induces platelet aggregation and blockade of this 
production will result in irreversible inhibition of platelet aggregation [23]. 
Figure 5. Molecular structure of acetyl-
salicylic acid. https://commons.wiki
media.org/wiki/File:Aspirin-skeletal.svg 
Public domain. 
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P2Y12-receptor antagonists 
ADP can induce platelet aggregation by binding to the G-protein coupled 
receptors P2Y1 [27] and P2Y12 [28, 29]. The co-activation of both the P2Y1- 
and the P2Y12-mediated pathway is required for a normal ADP-induced 
aggregation [30-32]. P2Y12-receptor antagonists such as clopidogrel and 
ticagrelor bind to the P2Y12-receptor and inhibit ADP-induced aggregation. 
The antagonists have different mechanisms of action [33]. Clopidogrel is a 
thienopyridine and a pro-drug that needs to be metabolized in the liver to 
become active (Figure 7). The active metabolite binds irreversibly to the 
P2Y12-receptor which modifies the ADP-binding site [34] and thus inhibits 
ADP-induced platelet aggregation (Figure 6). As clopidogrel inhibition is 
irreversible, it will last for the whole life-span of the platelet. The hepatic 
metabolism of clopidogrel is dependent on the cytochrome P450 and genetic 
variation in the cytochrome P450 isozymes results in a varied response to 
Figure 6. Schematic illustration of a platelet with a number of receptors, activation
pathways and targets of the antiplatelet agents acetylsalicylic acid, ticagrelor and
clopidogrel. ADP: adenosine diphosphate; ASA: acetylsalicylic acid; COX-1:
cyclooxygenase-1; GP: glycoprotein; PAR: protease-activated receptor; TP: thromboxane
receptor; TXA2: thromboxane A2; vWF: von Willebrand factor.   
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clopidogrel treatment [35-37]. The occurrence of non-responders has 
SUHYLRXVO\EHHQUHSRUWHGWREHEHWZHHQ௅[38]. 
Ticagrelor (Figure 8) is a P2Y12-receptor antagonist that binds to the receptor 
non-competitively with ADP [39]. It binds reversibly and locks the receptor 
in an inactive state [39] and thus inhibits ADP-induced aggregation (Figure 
6). It has a faster onset than clopidogrel in stable coronary artery disease 
patients [40] as it is active in its native form as well as produces an active 
metabolite [39]. It also has a faster offset in these patients [40] with a plasma 
half-OLIHRI௅K[33].  
Figure 8. Molecular structure of ticagrelor. https://en.
wikipedia.org/wiki/File:Ticagrelor.svg Public domain. 
Figure 7. Conversion of clopidogrel (upper left) to its active metabolite (upper
right). https://commons.wikimedia.org/wiki/File:Clopidogrel_activation.svg Public
domain. 
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There are currently no commercially available antidotes to the P2Y12-receptor 
antagonists and the treatment is therefore discontinued 3‒5 days before non-
emergent cardiac and non-cardiac surgery [41] while ASA treatment is 
continued. However, in a significant portion of ACS patients, the P2Y12-
receptor antagonists cannot be discontinued before surgery due to e.g. 
ongoing myocardial ischemia, alarming angiographic findings or recent 
coronary stenting. In a recent national study from Sweden, 40% of ACS 
patients undergoing CABG were operated after a shorter P2Y12-receptor 
antagonist discontinuation period than recommended [15]. This means that 
the patients underwent surgery with ongoing potent platelet inhibition. For 
these patients, there is a need for a strategy to reduce bleeding complications. 
1.4 Platelet concentrates 
Today, transfusions of different blood products such as red blood cells, 
platelets, plasma, and coagulation factor concentrates are used to improve 
hemostasis in patients with ongoing bleeding. Transfusion of platelet 
concentrates is used to treat bleeding complications if it is suspected that low 
platelet count or platelet dysfunction contributes to the bleeding. Platelet 
concentrates can be prepared using different methods. Apheresis platelet 
concentrates are prepared using an apheresis device which separates platelets, 
together with some plasma, from the other blood components which are 
returned to the donor. As only platelets are retrieved from the donor and not 
whole blood, more platelets can be collected compared to whole blood 
donations which are restricted to the amount of red blood cells one can safely 
collect from an individual. Thus a sufficient amount of platelets are collected 
from a single donation to yield at least one platelet unit. Buffy-coat platelet 
concentrates are prepared from whole blood donations in a two-step process. 
The blood components are separated using centrifugation and a blood 
expander platform. After removal of red blood cells and plasma, the resulting 
buffy-coat can be used for platelet concentrate preparation. Buffy-coats from 
multiple donors and storage medium are pooled together in order to yield one 
platelet unit after a second centrifugation step. Interim platelet unit (IPU) 
concentrates are also prepared from whole blood donations but only require 
one platform for centrifugation and separation [42]. Using a separation 
platform, an IPU containing platelets in plasma and the blood components are 
separated. IPUs from multiple donors are pooled together with storage 
medium to yield one platelet unit. 
The platelets can be stored in different media such as plasma and/or different 
platelet additive solutions (PAS) which, for instance, provide buffering 
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substances to maintain the pH [43, 44]. The aim is to keep the platelets in an 
inactivated state as well as to maintain the platelets’ ability to aggregate in 
response to agonists. The platelet concentrates are stored in a platelet 
incubator at room temperature with horizontal agitation until use or for a 
maximum of 7 days. However, storage at room temperature influences the 
platelet quality negatively, a process referred to as platelet storage lesion [45, 
46]. This includes changes in platelet morphology and an impaired platelet 
function. Current routine assays used in transfusion medicine for quality 
assessment of platelet concentrates include visual inspection as well as 
measuring platelet concentration, pH, glucose and lactate levels [46-48]. The 
platelets’ ability to aggregate in response to agonists has also been shown to 
attenuate over time in stored platelet concentrates [45] and platelet activation 
increases and can thus be used to monitor platelet storage lesion [46].  
1.5 New potential treatment strategy 
Platelet transfusion can restore AA-induced aggregation inhibited by ASA 
[49] while it only has a small or no effect on the ADP-dependent pathway 
inhibited by P2Y12-receptor antagonists [49-51]. In previous studies, the 
perioperative bleeding risk in patients undergoing cardiac surgery with 
P2Y12-receptor antagonist treatment is associated to the their preoperative 
ADP-dependent platelet aggregation response [52-54]. A potential strategy to 
reduce bleeding complications in these patients could be one that improves 
ADP-dependent platelet aggregation. 
Adrenergic agents 
Adrenaline and noradrenaline (Figure 9) are catecholamines released from 
two main sources in the human body. Adrenaline is synthesized and released 
by chromaffin cells in the adrenal medulla while noradrenaline is mainly 
released from sympathetic nerve endings and to some extent from the adrenal 
medulla [55]. Noradrenaline can be converted to adrenaline by the enzyme 
phenylethanolamine-N-methyltransferase in the adrenal medulla [55]. These 
catecholamines are involved in the body’s “fight or flight” response 
(response to stressful or fearful situations) and are released from the adrenal 
medulla upon acetylcholine stimulation of the nicotinic acetylcholine 
receptors located on the chromaffin cell membrane [56]. After their release, 
adrenaline and noradrenaline bind to adrenergic receptors on effector cells. 
The adrenergic receptors are G-protein coupled receptors and are divided into 
α-receptors and β-receptors. Adrenaline and noradrenaline bind to α-receptors 
causing vasoconstriction but can also bind to β-receptors which causes 
vasodilation [57-59]. The release of these catecholamines increases cardiac 
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output as activation of adrenergic receptors in the myocardium results in an 
increased heart rate and myocardial contractility [60-62]. Due to these 
effects, adrenaline and noradrenaline are commonly used in cardiac surgery 
to increase blood pressure during and after CPB. 
 
Effects of adrenergic agents on platelets 
3ODWHOHWVH[SUHVVERWKĮ- DQGȕ-receptors [63]. In studies on untreated human 
platelets, supplementation with adrenaline or noradrenaline caused mild 
aggregation by activation of Į-receptors [63-65]. The results also indicated 
that adrenaline was more potent than noradrenaline in inducing platelet 
aggregation [63-65]. These catecholamines also potentiate ADP-induced 
aggregation of human platelets without antiplatelet agents present [64]. In 
addition, adrenaline has been shown to potentiate ADP-induced aggregation 
in blood samples from clopidogrel-treated patients [66] and in platelet-rich 
plasma from healthy subjects where the P2Y12-receptor antagonists prasugrel, 
cangrelor, ticagrelor or the active metabolite of clopidogrel had been added in 
vitro [67]. The potentiation may be due to the molecular mechanisms of these 
substances affecting platelet signaling pathways. ADP induces platelet 
activation and aggregation by binding to the G-protein coupled receptors 
P2Y1 [27] and P2Y12 [28, 29]. The binding of ADP to P2Y1 activates the G-
protein Gq which results in the activation of phospholipase C and consequent 
increase in cytosolic level of calcium ions, initiating the platelet activation 
and aggregation response (Figure 10) [27]. When ADP binds to P2Y12, the G-
protein Gi inhibits adenylyl cyclase and activates phosphoinositide 3-kinase 
(PI3K) which activates downstream effector molecules (Figure 10) [68-70]. 
The inhibition of adenylyl cyclase results in a reduced level of cyclic 
adenosine monophosphate (cAMP) and although an increased level of cAMP 
inhibits platelet activation, the reduced level does not directly affect platelet 
aggregation [71-74]. Activation of PI3K and subsequent activation of 
Figure 9. Molecular structures of noradrenaline (left) and adrenaline (right).
https://commons.wikimedia.org/wiki/File:Noradrenaline2.svg 
https://sv.m.wikipedia.org/wiki/Fil:Adrenaline.svg Public domain. 
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downstream effector molecules result in granule secretion [74]. The co-
activation of both the P2Y1- and P2Y12-mediated pathway is required for a 
normal ADP-induced activation and aggregation [30-32]. P2Y12-receptor 
antagonists such as ticagrelor act by inhibiting the ADP-induced activation of 
P2Y12. Adrenaline and noradrenaline can ELQG WR Į-receptors [63-65]. 
Adrenaline binds to tKH Į2A-receptor which is coupled to the G-protein Gz 
(Figure 10). Binding of adrenaline results in inhibition of adenylyl cyclase 
[31, 75] and activation of PI3K [68] thus mimicking the P2Y12-mediated 
pathway (Figure 10) [72]. Therefore, adrenaline may potentiate ADP-induced 
aggregation in the presence of P2Y12-receptor antagonists as responses from 
both signaling pathways can be achieved.  
Infusion of adrenaline (0.07 μg/kg/min) has previously improved platelet 
aggregation in healthy volunteers without antiplatelet therapy [76]. Infusion 
of noradrenaline (0.03 and 0.14 μg/kg/min) has also increased platelet 
aggregation in untreated healthy volunteers [77]. In another study on both 
healthy volunteers and hypertensive patients, the ADP-induced aggregation 
increased after infusion of noradrenaline (0.1 μg/kg/min) [78]. No previous 
studies assessing the effect of adrenaline or noradrenaline infusion on platelet 
function in subjects with ongoing antiplatelet therapy have been conducted. 
Infusion of adrenaline or noradrenaline to increase platelet activation and 
aggregation could be a potential strategy for prevention of bleeding 
complications in cardiac surgery patients with ongoing or recently 
Figure 10. Schematic illustration of intracellular signaling in 
response to binding of ADP and adrenaline to their respective G-
protein coupled receptors P2Y1, P2Y12 DQG Į2A. AC: adenylyl 
cyclase; ADP: adenosine diphosphate; cAMP: cyclic adenosine
monophosphate; PI3K: phosphoinositide 3-kinase; PLC:
phospholipase C.  
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discontinued antiplatelet therapy. In two previous randomized trials, 
perioperative infusion of low dose adrenaline (0.05 µg/kg/min) in 
combination with the antifibrinolytic agent tranexamic acid during total hip 
arthroplasty reduced early postoperative total blood loss compared to placebo 
groups receiving saline solution [79, 80].  
1.6 Platelet function testing 
Various methods that target different phases of platelet function can be used 
to assess the function. 
Activation 
One phase of platelet function is platelet activation. This can be studied with 
flow cytometry using various fluorescently-labeled antibodies or reagents 
binding to different platelet activation markers. Flow cytometry allows for 
the simultaneous analysis of various activation-dependent changes [81]. In 
this method, anticoagulated whole blood or platelet suspension is diluted and 
added to fluorescently-labeled antibodies or reagents. Markers expressed on 
the surface membrane of activated platelets include the granula proteins P-
selectin [82, 83] and CD63 [84] as well as activated fibrinogen receptor GP 
IIb/IIIa (which PAC-1 binds to) [85] and the phospholipid phosphatidylserine 
[86, 87]. To distinguish platelets from other cells in whole blood, an antibody 
binding to a platelet surface marker such as CD61 or glycoprotein Ib (GPIb, 
also referred to as CD42b) can be used. Antibodies binding to platelet surface 
markers will bind to both resting and activated platelets. Agonists such as 
ADP, thrombin receptor-activating peptide-6 (TRAP) and collagen may be 
added to study platelet reactivity [81]. 
In this method, the sample is placed in the flow cytometry instrument and 
follows a liquid stream into the apparatus (Figure 11). Droplets are formed by 
a vibrating nozzle. The droplets go past one or multiple laser beams which 
will excite the fluorophores and the emitted fluorescence and light-scatter are 
recorded by detectors. Platelets can be identified by their light-scatter 
properties and by the platelet surface marker. The median fluorescence 
intensity or the percentage of platelets expressing the activation marker can 
be used to quantify platelet activation [81].  
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Aggregation 
Another phase of platelet function is platelet aggregation. Light-transmission 
aggregometry (LTA) is considered the gold standard for studying platelet 
function in vitro. It was first published by Born and O’Brien in 1962 [88, 89]. 
Anticoagulated whole blood is centrifuged and the resulting platelet-rich 
plasma and platelet-poor plasma can be utilized in this method. Low shear 
platelet aggregation is analyzed by measuring the change in optical density 
after agonists, such as ADP, adrenaline, AA and collagen have been added to 
platelet-rich plasma. When the platelets aggregate, the sample become less 
turbid resulting in a diminished light absorbance and increased light 
transmission. The platelet-poor plasma is used as a blank to set the limit for 
no aggregation. Disadvantages with LTA include it being time-consuming, 
requiring a large volume of blood and sample preparation [90, 91]. 
Point-of-care (POC) tests for measuring platelet function have been 
developed for a simpler, faster and more standardized analysis. One example 
is the VerifyNow® system (Accumetrics, San Diego, CA, USA), which is a 
fully-automated whole blood analysis that measures platelet aggregation. In 
this method, the binding of platelets to fibrinogen-coated polystyrene beads 
in response to ADP and prostaglandin E1, AA or TRAP is detected for 
monitoring antiplatelet therapy. When the platelets bind to the beads, the light 
transmission increases which will be detected in the instrument. The results 
are expressed in reaction units based on the rate and degree of aggregation 
[92].  
Another POC method is whole blood impedance aggregometry such as the 
commercially available Multiplate® (Roche Diagnostics, Basel, Switzerland) 
(Figure 12). In this method, anticoagulated blood is added to test cells at 
37°C. The Multiplate aggregometer has five channels which enable parallel 
Figure 11. A flow cytometer (left) and the principle of flow cytometry (right).  
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testing using different agonists such as ADP, AA, collagen and TRAP. The 
test cell contains a magnetic stirrer and two sets of electrodes (Figure 12). 
After the agonists have been added, the platelets aggregate on the electrodes 
which will cause the impedance between the electrodes to increase. This is 
measured for 6 minutes. As each test cell contains two sets of electrodes, the 
results will be presented as two aggregation curves. The area under the 
aggregation curve (AUC) (mean value of the two curves), measured in 
aggregation units (U), is used to quantify platelet aggregation. Multiplate has 
been used in previous studies which showed that the bleeding risk in cardiac 
surgery patients with ongoing or recently discontinued treatment with a 
P2Y12-receptor antagonist correlates to the residual ADP-dependent platelet 
aggregation [52-54].  
 
 
Figure 12. The Multiplate® analyzer (left), a test cell with two electrode pairs (upper
right) and an example of a resulting aggregation curve (lower right). AUC: Area under
curve. 
Platelet activation and aggregation: Clinical and experimental studies 
16 
1.7 Clot formation testing 
Different methods of monitoring clot formation exist. Two standard 
screening methods are prothrombin time (PT) test and activated partial 
thromboplastin time (APTT). The PT test utilizes thromboplastin (containing 
tissue factor and phospholipids) to extrinsically activate clot formation and is 
sensitive for abnormalities of factors V, VII, and X, prothrombin and 
fibrinogen [93]. Citrated platelet-poor plasma is incubated with 
thromboplastin at 37°C and calcium is then added. The time it takes to 
formation of fibrin filaments is the PT [93]. To standardize PT, the 
international normalized ratio (INR) can be calculated by dividing the PT for 
the patient sample with the PT for normal plasma. To study intrinsic 
activation of clot formation, the APTT test can be used. In this test, partial 
thromboplastin (phospholipids) in combination with an activator of the 
contact pathway, such as silica or ellagic acid, is used to intrinsically activate 
clot formation. The APTT test is sensitive for abnormalities of factors V, 
VIII, IX, X, XI, XII, prothrombin and fibrinogen [93]. Citrated platelet-poor 
plasma is incubated with partial thromboplastin and an activator at 37°C and 
then calcium is added. The time it takes to formation of fibrin filaments is the 
APTT [93]. A drawback with the PT and APTT tests is that it requires 
plasma preparation from whole blood. 
POC tests for assessing clot formation have been developed for a more 
standardized analysis without the need for sample preparation. These include 
thromboelastography (TEG®; Haemonetics Corporation, Braintree, MA, 
USA) and thromboelastometry (ROTEM®; Pentapharm GmbH, Munich, 
Germany) [94, 95]. Both TEG and ROTEM are viscoelastic methods. In 
TEG, anticoagulated whole blood is added to a test cup at 37°C and a pin that 
is coupled to a computer through a torsion wire is suspended into the cup. 
The test cup oscillates and as a clot starts to form, the pin will become 
restrained thus creating tension in the wire which will be mechanically 
detected and processed by the computer [94, 95]. From the resulting graph, 
multiple parameters are obtained. These include reaction time (s), which is 
the time it takes from the start of the test to the formation of a clot with an 
amplitude of 2 mm, and maximum amplitude (mm) which reflect the clot 
strength.  
ROTEM is a modified version of TEG. In ROTEM, anticoagulated blood is 
added to a test cup and activators of clot formation are added at 37°C. The 
sample cup is then placed so that an oscillating pin is suspended into the cup. 
As a clot starts to form, the pin becomes increasingly limited in its 
movement. The device optically detects the change in movement yielding a 
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graph from which multiple parameters are obtained [94]. These include 
clotting time (s) (equivalent to reaction time), clot formation time (s) and 
maximum clot firmness (mm) (equivalent to maximum amplitude) (Figure 
13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The ROTEM® delta instrument (left)
and an example of a resulting graph (right). CT:
clotting time; CFT: clot formation time; MCF:
maximum clot firmness. 
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2 AIMS 
The overall aim of this thesis was to identify and evaluate current and new 
potential methods to prevent and reduce perioperative bleeding complications 
in patients with ongoing antiplatelet therapy. 
The specific aims were 
1. To compare the new interim platelet unit (IPU) concentrates 
with the more established buffy-coat and apheresis platelet 
concentrates in terms of platelet storage lesion markers 
(Study I) 
 
2. To investigate the in vitro effects of adrenaline 
supplementation, alone or combined with platelet 
concentrate, on platelet aggregation and activation in blood 
samples from patients with ongoing DAPT with ASA and 
ticagrelor (Study II) 
 
3. To investigate the effect of adrenaline infusion on platelet 
aggregation, activation and clot formation in ticagrelor-
treated healthy volunteers (Study III) 
 
4. To investigate the effect of intraoperative noradrenaline 
infusion on platelet aggregation and clot formation in 
patients undergoing coronary artery bypass grafting (Study 
IV) 
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3 METHODS 
3.1 Participants 
In Study I, platelet concentrates from blood donors at Sahlgrenska University 
Hospital were evaluated. All donors signed the health questionnaire, which 
specifies that blood components may be used for research and quality 
assurance purposes, before donation. This study was part of the internal 
evaluation and regarded as quality assurance for the introduction of a new 
type of platelet concentrate at the hospital. Studies II‒IV were approved by 
the Regional Research Ethics Committee in Gothenburg, Sweden, and were 
conducted according to the Declaration of Helsinki. Studies III and IV were 
approved by the Swedish Medical Products Agency and Study IV was also 
approved by Sahlgrenska Radiation Safety Committee. All participants gave 
written informed consent.  
In Study II, blood samples from in-hospital ACS patients on ongoing DAPT 
with ASA and ticagrelor were included. Exclusion criteria were known 
bleeding disorder, renal or liver disease. In Study III, only healthy men were 
included to avoid the effect of the hormone cycle on platelet function [96]. 
The following exclusion criteria were applied: chronic or mental disease, age 
above 40 years, former intracranial bleeding, abnormalities in 
electrocardiography (ECG), chronic medication, and any occasional intake of 
non-steroidal anti-inflammatory drugs, acetylsalicylic acid or any other 
substances that may interact with ticagrelor, adrenaline or metoprolol less 
than one week before the investigational visit.  Additional exclusion criteria 
were known intolerance or contraindication to ticagrelor, adrenaline or 
metoprolol or known drug abuse of any kind. In Study IV, patients planned 
for elective CABG during May 2017-January 2018 were asked to partake in 
the study when the required research means were available. The following 
exclusion criteria were applied: hypersensitivity to 125I-Albumine, 
contraindication for radioactive contrast, age below 40 years, diabetes 
mellitus, previous stroke, untreated hypertension, pregnancy, breast-feeding, 
a known carotid artery stenosis, and/or left ventricular systolic ejection 
fraction of 45% or less. The characteristics of all the study participants are 
given in Table 1.  
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Table 1. Characteristics of participants in Studies II‒IV. Median and interquartile range or 
number. 
 Study II 
 
Study III 
 
Study IV 
 Adrenaline in 
vitro 
Adrenaline in 
vivo 
Control Noradrenaline 
n 40 10 12 12 
Female/male gender 7/33 0/10 3/9 2/10 
Age (years) 64 (54‒73) 24 (19‒30) 67 (64‒69) 64 (55‒69) 
Height (m) 1.79 
(1.71‒1.82) 
1.82 
(1.76‒1.93) 
1.71 
(1.69‒1.76) 
1.81 
(1.74‒1.87) 
Weight (kg) 85 (76‒95) 83 (74‒103) 80 (77‒82) 85 (74‒91) 
BMI (kg/m2) 27 (25‒29) 24 (23‒30) 28 (25‒29) 25 (24‒27) 
Diabetes mellitus 4 (10%) 0 0 0 
Hemoglobin (g/L) 138 
(131‒156) 
145 
(141‒151) 
146 
(139‒152) 
143 
(135‒148) 
Platelet concentration 
(× 109/L) 
210 
(183‒262) 
235 
(222‒249) 
204 
(190‒241) 
256 
(232‒306) 
 
3.2 Study procedure 
Study I 
Platelet concentrates prepared by the regional blood bank at Sahlgrenska 
University Hospital, according to local routines in agreement with European 
guidelines [48], were evaluated. The new IPU concentrates (n=10) were 
compared to buffy-coat (n=10) and apheresis platelet concentrates (n=10) 
during the 7-day storage period (Figure 14). All platelet concentrates were 
leukocyte-reduced (<1 × 106 leukocytes per unit) and gamma-irradiated (25 
Gray). After preparation, the platelet concentrates were stored in a platelet 
incubator at 22°C with horizontal agitation until use.  
IPU platelet concentrates were prepared from whole blood donations. Whole 
blood (anticoagulated with citrate, phosphate and dextrose) was separated 
using the processing program 3C in the Reveos system (Terumo BCT 
Europe) yielding one unit of red blood cells, one unit of plasma and one 
interim platelet unit (IPU) as well as a waste pack with leukocytes. The 
resulting IPU contained approximately 30 mL plasma and was incubated 
overnight (22°C) with horizontal agitation. Four IPUs were then pooled 
together with PAS (SSP+) to a target count of approximately 250 × 109 
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platelets/unit. The plasma carryover in the IPU concentrates was 
approximately 40%.  
Buffy-coat platelet concentrates were also prepared from whole blood 
donations. Whole blood (anticoagulated with citrate, phosphate and dextrose) 
was centrifuged and separated into its components using a blood expander 
platform. After the resulting buffy-coat had been incubated overnight (22°C) 
with horizontal agitation, four buffy-coats were pooled together with PAS 
(SSP) giving rise to one unit. For the elimination of residual red blood cells, 
the pooled unit was further processed using a blood component processing 
device (TACSI). The plasma carryover in the buffy-coat platelet concentrates 
was approximately 20%. 
Apheresis platelet concentrates were collected according to standard 
protocols (Trima Accel; Terumo BCT Europe) from donors with a platelet 
concentration of 230 × 109/L before donation. The target platelet 
concentration was 1,600 × 109/L and the whole blood to citrate ratio was 
10:1. The resulting platelet concentrates consisted of platelets in autologous 
plasma and were subjected to a 2-hour rest period before further handling. 
On days 1, 4 and 7 after donation, metabolic parameters (pH, lactate and 
glucose) were measured in all platelet concentrates and platelet activation 
was evaluated with flow cytometry. In addition, agonist-induced platelet 
aggregation was evaluated using impedance aggregometry.  
Figure 14. Interim platelet unit (IPU), buffy-coat (BC) and apheresis platelet concentrates
(PC) were prepared and then sampled on day 1, 4 and 7 after donation (Study I).  
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Study II 
In this study, blood samples from patients on DAPT with ASA and ticagrelor 
were collected for platelet aggregation and activation analysis. The blood 
samples were supplemented with adrenaline, apheresis platelet concentrates, 
and/or ADP. First, the effect of five plasma concentrations of adrenaline in 
the blood sample (6 nM, 27 nM, 82 nM, 153 nM and 770 nM) on ADP- and 
AA-induced aggregation was evaluated with impedance aggregometry 
(n=10) (Figure 15). 
Next, adrenaline (770 nM) was added alone or in combination with apheresis 
platelet concentrate to investigate the effect on ADP- and AA-induced 
aggregation (n=10) (Figure 16). The apheresis platelet concentrates were 
prepared according to the methods section for Study I and stored for a median 
RI  UDQJH௅ GD\ The addition of 120 × 106 platelets to a 1 mL blood 
sample was evaluated which approximately corresponds to an increase in 
platelet count achieved by transfusion of three apheresis units to a 70 kg 
patient. 
Figure 15. Adrenaline supplementation to blood samples.
Concentrations are the resulting plasma concentrations
of adrenaline in the blood sample (Study II). 
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Lastly, adrenaline (770 nM) was added alone or combined with ADP to 
evaluate their effect and possible potentiation of platelet aggregation (n=10) 
and activation (n=10) using flow cytometry (Figure 17).  
Study III 
This study was a proof-of-concept study performed on healthy volunteers 
(n=10). During a screening visit, information about medical history was 
collected and a physical examination was performed which included heart 
and lung auscultation, height, weight, blood pressure and heart rate 
registrations and electrocardiography (ECG). Furthermore, laboratory testing 
was conducted and included hemoglobin and platelet concentration, 
Figure 17. Supplementation with adrenaline
(Adr) and ADP to blood samples (Study II). 
Figure 16. Supplementation with platelet
concentrate and adrenaline (Adr) to blood
samples (Study II). 
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electrolytes, liver function tests and a urine drug test. If the participant was 
still qualified for study participation, the investigational visit was conducted 
within 21 days.  
During the investigational visit, the study participants were treated with 
ticagrelor (2x90 mg) and an increasing infusion of adrenaline (0.01, 0.05, 
0.10, 0.15 μg/kg/min) was administered according to Figure 18. Lastly, WKHȕ-
blocker metoprolol (5 mg) was intravenously given in combination with the 
highest dose of adrenaline. Registrations of blood pressure, heart rate and 
perceived dyspnea (Borg scale ௅) and blood samples were collected at 
seven time-points (Figure 18) with a maximum deviation of 3 minutes 
accepted at each time-point. Impedance aggregometry was used to assess 
platelet aggregation while flow cytometry was used to measure platelet 
activation. Clot formation was evaluated with thromboelastometry. If the 
participant’s systolic blood pressure increased to over 180 mmHg or the heart 
rate increased to over 120 beats/min, the adrenaline infusion would be 
terminated according to the study protocol. 
Phone follow-up calls to the participants were conducted 1 and 3 days after 
the investigational visit to record any potential adverse events after their visit. 
 
 
 
 
 
Figure 18. Flow chart of treatment during the investigational visit (Study III). 
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Study IV 
Study IV was a randomized controlled trial where 24 CABG patients were 
randomized to either maintenance of pre-anesthesia mean arterial pressure 
(MAP) by noradrenaline infusion until 50 minutes after anesthesia induction 
(before start of CPB) or standard treatment (noradrenaline infusion only if 
MAP below 60 mmHg and/or as a complement to the Trendelenburg 
position) (Figure 19). Block randomization with sealed envelopes was used 
to guarantee that the distribution of the treatment (maintenance of MAP or 
standard treatment) was equal within the gender group. Registrations of MAP 
and blood samples were collected 10 minutes before anesthesia induction and 
50 minutes after induction. Platelet aggregation was assessed with impedance 
aggregometry and clot formation was assessed with thromboelastometry. 
Study IV was a predefined substudy to a trial investigating plasma volume 
changes in relation to blood pressure. 
 
 
 
Figure 19. )ORZ FKDUW RI WKH UDQGRPL]DWLRQ DQG WUHDWPHQW 6WXG\ ,9 MAP: mean arterial
pressure. 
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3.3 Analyses 
Flow cytometry 
In Studies I‒III, flow cytometry (FACSCalibur flow cytometer) was used to 
assess platelet activation. In all three studies, 10,000 positive platelet events 
were analyzed and the percentages of platelets expressing the platelet 
activation markers were reported. To set the limit between positively and 
negatively stained platelets, background control samples were used which 
show the nonspecific binding of the antibodies. The limit is set to obtain 
approximately 1 to 2% positive platelets in the background control samples 
[97].  
In Study I, the unstimulated (spontaneous) activation during storage of 
platelet concentrates was evaluated by measurement of expression of the 
platelet granule proteins P-selectin and CD63 and exposure of 
phosphatidylserine.  Antibodies and reagents for the platelet activation 
markers and prepared platelet concentrate were added to tubes. After 15 
minutes of incubation and subsequent dilution, flow cytometry was 
performed within 30 minutes. 
In Studies II and III, both spontaneous and agonist-induced platelet activation 
was evaluated by measuring expression of P-selectin and binding of PAC-1 
(binds to activated fibrinogen receptor GP IIb/IIIa). Whole blood was 
collected in hirudin tubes (0.15 mg/L). Duplicate samples containing either 
no agonist (unstimulated), adrenaline alone (plasma concentration 770 nM), 
ADP alone (6.5 µM) or a combination of adrenaline and ADP were prepared 
in Study II. In Study III, duplicate samples containing either no agonist, ADP 
(6.5 µM) or TRAP (32 µM, positive control) were prepared. Antibodies 
binding to the activation markers and whole blood were added to tubes. After 
10 minutes of incubation and subsequent dilution, flow cytometry was 
performed within an hour in Study II and within 30 minutes after blood 
collection in Study III.  
Impedance aggregometry 
Impedance aggregometry (Multiplate®; Roche Diagnostics, Basel, 
Switzerland) was used to study platelet aggregation in all four studies. Whole 
blood was collected in hirudin tubes (0.15 mg/L). In this method, 300 µL of 
anticoagulated whole blood is added to 300 µL NaCl (9 mg/mL) in each test 
cell and allowed to incubate for 3 minutes at 37°C. Agonists are thereafter 
added to initiate aggregation and the impedance between two pairs of 
electrodes is measured for 6 minutes.  The two resulting aggregation curves 
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should not differ more than 20%. The AUC (U) was reported. In Study I, 
platelet concentrate was added instead of whole blood. Specifically, 150 µL 
platelet concentrate was added to 450 µL phosphate-buffered saline (PBS) for 
apheresis concentrates. For the IPU and buffy-coat platelet concentrates, 150 
µL of the PBS was replaced with 150 µL of allogeneic plasma of blood group 
AB. 
In Study I, the ADP, ASPI, TRAP and COL tests were used. The ADP test 
assesses P2Y12-receptor dependent aggregation using ADP as an agonist 
(final concentration 6.5 µM) while the ASPI test evaluates cyclooxygenase-
dependent aggregation (i.e. ASA-sensitive) using AA as an agonist (final 
concentration 0.5 mM). Further the TRAP test detects PAR1-receptor 
dependent aggregation (sensitive to GP IIb/IIIa antagonists) using TRAP-6 as 
an agonist (final concentration 32 µM) while collagen is used in the COL test 
to evaluate cyclooxygenase-dependent aggregation (final concentration 3.2 
mg/L). In Study II, the ADP high-sensitivity (ADP HS) and ASPI tests were 
used while in Studies III and IV, ADP HS, ASPI and TRAP tests were used. 
The ADP HS test evaluates P2Y12-receptor dependent aggregation with 
higher sensitivity than the ADP test by the use of ADP (final concentration 
6.3 µM) in combination with prostaglandin E1 (final concentration 9.4 nM). 
The reference ranges provided by the manufacturer for the ADP, ADP HS, 
ASPI, TRAP and COL tests in blood samples from healthy individuals are 
57‒113 U, 43‒100 U, 71‒115 U, 84‒128 U, and 72‒125 U, respectively 
when using double wall hirudin-anticoagulated blood tubes. 
Thromboelastometry 
Clot formation was assessed using thromboelastometry (ROTEM®; 
Pentapharm GmbH, Munich, Germany) in Studies III and IV.  Blood samples 
were collected in citrated tubes (0.109 M citrate). In this method, 300 µL of 
anticoagulated whole blood is added to a test cup and then an activator is 
added at 37°C. The EXTEM test was used in Study III while the EXTEM, 
FIBTEM, INTEM and HEPTEM tests were used in Study IV. The EXTEM 
and FIBTEM tests evaluate the extrinsically activated clot formation using 
tissue factor as an activator. In the FIBTEM test, cytochalasin D is also added 
to inhibit the platelet contribution to clot formation. In the INTEM test, clot 
formation is intrinsically activated by addition of ellagic acid and partial 
thromboplastin phospholipid. As the INTEM test is sensitive for heparin, the 
HEPTEM test can be used to eliminate the effect of heparin by the addition 
of heparinase together with the same activators as in the INTEM test. The 
clotting time, clot formation time and maximum clot firmness were reported. 
The clotting time is the time from the start of the test until the clot reaches an 
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amplitude of 2 mm while the clot formation time is the time it takes from an 
amplitude of 2 mm until 20 mm is reached. The maximum clot firmness is 
the maximum amplitude that is reached during the test reflecting clot 
strength.  
3.4 Statistics 
Data are presented as median with interquartile range (25th‒75th percentiles).  
Study I 
IPU platelet concentrates were compared with buffy-coat concentrates and 
with apheresis concentrates using the Mann-Whitney U test at each sampling 
time-point. The tests were conducted at a significance level of 0.05 and 
performed with SPSS Statistics version 22 (IBM Corporation, Armonk, NY, 
USA).  
Study II 
Comparisons of continuous data before and after addition of the substances 
were performed using the Friedman test for repeated measures. The tests 
were conducted at a significance level of 0.05. In order to find the pairs of 
samples that differed significantly, the Wilcoxon signed-rank test (matched 
pairs) was used with Bonferroni-Holm correction [98]. The statistical 
analyses were performed with SPSS Statistics version 22 (IBM Corporation, 
Armonk, NY, USA). 
Study III 
Comparisons of continuous data between the seven different blood sampling 
time-points were conducted with the Friedman test. The tests were conducted 
at a significance level of 0.05. In order to find the pairs of samples that 
differed significantly, Wilcoxon signed-rank test was used. The sample size 
was based on preliminary results from Study II where a mean difference in 
ADP-induced aggregation after adrenaline supplementation (153 nM) was 8.6 
U with a standard deviation of the difference of 8.7 U. A sample size of 8 
study participants was needed to achieve 80% power to detect such a 
difference with a two-sided test at a significance level of 0.05. A sample size 
of 10 study participants was chosen to account for any discontinued 
participation. The statistical analyses were performed with SPSS Statistics 
version 22 (IBM Corporation, Armonk, NY, USA).  
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Study IV 
Within each randomization group, values at 10 minutes before and 50 
minutes after anesthesia induction were compared using Wilcoxon signed-
rank test. To compare continuous data between the two randomization 
groups, the Mann-Whitney U test was used. Two secondary analyses were 
performed. In one analysis, the patients were allocated according to if they 
had ongoing noradrenaline infusion at 50 minutes after induction or not. In 
the other analysis, one patient was excluded due to not having ongoing ASA-
treatment. Furthermore, regression models with natural cubic splines were 
used to evaluate the effect of noradrenaline infusion rate on the changes in 
platelet aggregation between the two time-points. Piecewise linear functions 
were used to simplify the splines. The difference in Least Squares Means 
(∆LSM) with 95% Confidence Intervals (CI) is presented for each 0.01 
µg/kg/min increase in noradrenaline infusion rate. The tests were conducted 
at a significance level of 0.05. No separate power analysis was conducted for 
this substudy. Statistical analyses were performed with SPSS Statistics 
version 22 (IBM Corporation, Armonk, NY, USA) and SAS Software 
version 9.4 (SAS Institute Inc., Cary, NC, USA).  
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4 RESULTS 
4.1 Comparison of stored platelet concentrates 
(Study I) 
Platelet concentration and metabolic parameters 
Comparing IPU and buffy-coat platelet concentrates, the platelet 
concentration did not significantly differ while the rates of lactate production 
and glucose consumption were significantly lower in IPU concentrates 
(p=0.003 and p=0.022 respectively on day 4, and p=0.002 and p<0.001 
respectively on day 7) (Table 2). Furthermore, a higher pH was observed in 
IPU concentrates (p=0.002 on day 1, and p<0.001 on days 4 and 7). 
Table 2. Platelet concentration and in vitro metabolic parameters of interim platelet unit 
concentrates (IPU PCs), buffy-coat PCs, and apheresis PCs during storage (n=10 for each). 
Values on day 1 were used as reference points for the calculation of lactate production and 
glucose consumption. Median and interquartile range. ***p<0.001, **p<0.01 compared to 
IPU PCs at the same time-point of sampling. PLT: platelets.  
Days after donation Day 1 
 
Day 4 
 
Day 7 
Platelet concentration 
 (× 109/L) 
   
     IPU PCs 804 (758‒858) 772 (749‒834) 729 (711‒826) 
     Buffy-coat PCs 893 (864‒965) 854 (833‒913) 856 (809‒911) 
     Apheresis PCs     1,872 
(1,701‒1,971)*** 
1,860 
(1,731‒1,908)*** 
1,841 
(1,735‒1,884)*** 
Lactate production rate 
(mmol/1012 PLT/day) 
   
     IPU PCs  1.0 (0.8‒1.1) 1.2 (1.1‒1.5) 
     Buffy-coat PCs  1.3 (1.2‒1.4)** 1.7 (1.6‒1.7)** 
     Apheresis PCs  1.1 (1.0‒1.2) 1.2 (1.1‒1.2) 
Glucose consumption rate 
(mmol/1012 PLT/day) 
   
     IPU PCs  0.4 (0.4‒0.5) 0.5 (0.4‒0.6) 
     Buffy-coat PCs  0.6 (0.5‒0.7)* 0.8 (0.8‒0.9)*** 
     Apheresis PCs  0.5 (0.4‒0.7) 0.6 (0.6‒0.8)** 
pH    
     IPU PCs 7.30 (7.27‒7.30) 7.43 (7.39‒7.43) 7.39 (7.33‒7.41) 
     Buffy-coat PCs 7.23 (7.22‒7.27)** 7.30 (7.29‒7.32)*** 6.98 (6.94‒7.06)*** 
     Apheresis PCs 7.45 (7.40‒7.48)*** 7.42 (7.38‒7.46) 7.21 (7.11‒7.27)** 
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Comparing IPU and apheresis platelet concentrates, a lower platelet 
concentration was observed in IPU concentrates (p<0.001 for all) while the 
lactate production rate did not significantly differ (Table 2). A lower glucose 
consumption rate was observed in IPU concentrates at the end of the storage 
period (p=0.002 on day 7). A lower pH was observed in IPU concentrates in 
the beginning of storage (p<0.001 on day 1) while it was higher in IPU 
concentrates at the end of the storage period (p=0.002 on day 7). 
Platelet activation 
There were significant differences in the percentage of platelets expressing 
platelet activation markers between the different types of platelet 
concentrates during storage (Table 3). 
Table 3. Percentage of platelets expressing activation markers P-selectin, CD63, and 
phosphatidylserine in interim platelet unit concentrates (IPU PCs), buffy-coat PCs, and 
apheresis PCs during storage (n=10 for each). Median and interquartile range. ***p<0.001, 
**p<0.01, *p<0.05 in comparison to IPU PCs at the same time-point.  
Days after donation Day 1 
 
Day 4 
 
Day 7 
P-selectin (%)    
     IPU PCs 22.2 (18.6‒25.3) 18.2 (16.4‒21.2) 25.8 (25.0‒29.4) 
     Buffy-coat PCs 16.8 (15.4‒19.3)* 53.1 (46.2‒57.0)*** 62.6 (59.2‒65.9)*** 
     Apheresis PCs     5.0 (3.0‒14.9)* 11.8 (6.9‒16.0)* 19.5 (13.9‒24.9)* 
CD63 (%)    
     IPU PCs 15.4 (13.2‒18.0) 18.7 (13.6‒20.0) 20.7 (16.8‒21.9) 
     Buffy-coat PCs 8.3 (6.1‒10.1)** 29.0 (25.6‒35.4)*** 31.5 (26.3‒39.3)** 
     Apheresis PCs 11.0 (4.5‒24.4) 14.0 (7.0‒19.1) 15.3 (8.9‒19.2)* 
Phosphatidylserine (%)    
     IPU PCs 2.7 (2.6‒4.0) 5.1 (4.2‒5.9) 7.4 (5.6‒8.4) 
     Buffy-coat PCs 1.0 (0.9‒1.5)* 4.2 (3.1‒4.4)* 8.9 (8.2‒10.9)* 
     Apheresis PCs 1.5 (1.2‒1.8)** 2.8 (2.3‒3.1)*** 4.1 (3.2‒7.0)* 
 
Comparing IPU and buffy-coat platelet concentrates, a significantly higher 
percentage of platelets expressed the activation markers P-selectin (p=0.023), 
CD63 (p=0.001), and phosphatidylserine (p=0.028) in IPU concentrates in 
the beginning of the storage period (Table 2). However at the later time-
points, a lower percentage of platelets expressed P-selectin (p<0.001 for 
both) and CD63 (p<0.001 and p=0.001, respectively) in IPU concentrates. 
The percentage of platelets expressing phosphatidylserine was still higher on 
day 4 in IPU concentrates (p=0.045) but lower at the end of the storage 
period in IPU concentrates (p=0.034 on day 7). 
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Comparing IPU and apheresis platelet concentrates, more platelets expressed 
P-selectin (p=0.028 on day 1, and p=0.023 on days 4 and 7) and 
phosphatidylserine (p=0.001 on day 1, p<0.001 on day 4, and p=0.016 on day 
7) in IPU concentrates (Table 3). Also, a higher percentage of platelets 
expressed CD63 in IPU concentrates at the end of the storage period 
(p=0.034 on day 7).   
Platelet aggregation 
There were significant differences in agonist-induced platelet aggregation 
between the different types of platelet concentrates during storage (Table 4). 
Table 4. Adenosine diphosphate (ADP)-, arachidonic acid (AA)-, collagen (COL)- and 
thrombin receptor-activating peptide-6 (TRAP)-induced platelet aggregation in interim 
platelet unit concentrates (IPU PCs), buffy-coat PCs, and apheresis PCs during storage (n=10 
for each). Median and interquartile range. ***p<0.001, **p<0.01, *p<0.05 in comparison to 
IPU PCs at the same time-point. ND, not detectable 
Days after donation Day 1 
 
Day 4 
 
Day 7 
ADP (units)    
     IPU PCs ND ND ND 
     Buffy-coat PCs 2 (0‒4)** ND ND 
     Apheresis PCs     14 (10‒39)*** 1 (0‒4)** 0 (0‒0) 
AA (units)    
     IPU PCs 21 (9‒36) 18 (11‒32) 22 (10‒38) 
     Buffy-coat PCs 65 (48‒81)** 35 (26‒42) 0 (0‒0)** 
     Apheresis PCs 82 (74‒89)*** 76 (71‒87)*** 68 (62‒79)** 
COL (units)    
     IPU PCs 12 (10‒13) 7 (5‒9) 6 (5‒7) 
     Buffy-coat PCs 15 (12‒16) 10 (6‒10) 2 (2‒3)** 
     Apheresis PCs 29 (24‒45)** 11 (6‒15) 3 (1‒7) 
TRAP (units)    
     IPU PCs 74 (67‒77) 65 (57‒71) 65 (61‒67) 
     Buffy-coat PCs 67 (59‒72) 57 (54‒61) 42 (41‒49)** 
     Apheresis PCs 75 (70‒88) 72 (69‒79)* 69 (62‒75) 
 
Comparing IPU and buffy-coat platelet concentrates, a lower ADP-induced 
aggregation (p=0.002) and AA-induced aggregation (p=0.007) in IPU 
concentrates were observed in the beginning of the storage period (Table 4). 
However towards the end of storage, higher AA-, collagen-, and TRAP-
induced aggregation were observed in IPU concentrates (p<0.001 for all on 
day 7) (Table 4). 
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Comparing IPU and apheresis platelet concentrates, the ability of platelets to 
aggregate was significantly lower in IPU concentrates during storage (Table 
4). In the beginning of the storage period, lower ADP-, AA-, and collagen-
induced aggregation were observed in IPU concentrates (p<0.001, p<0.001, 
and p=0.001 respectively on day 1) (Table 4). On day 4 after donation, lower 
ADP-, AA-, and TRAP-induced aggregation were observed in IPU 
concentrates (p=0.005, p<0.001, and p=0.034). The AA-induced aggregation 
was still lower in IPU concentrates at the end of the storage period (p=0.001 
on day 7). 
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4.2 Supplementation with adrenaline, platelets 
and/or ADP (Study II) 
Effect of adrenaline 
on platelet 
aggregation 
Supplementation with 
adrenaline at resulting 
plasma concentrations of 
153 nM and 770 nM 
significantly increased 
ADP- (Figure 20A) and 
AA-induced aggregation 
compared to samples with 
no added adrenaline (n=10) 
(p=0.009 and p=0.007 for 
ADP, p=0.012 and p=0.007 
for AA, respectively). 
Aggregation did not 
significantly change after 
adrenaline supplementation 
at lower concentrations. 
Pooling the results from all 
aggregation trials (ADP: 
n=30, AA: n=20), the 
ADP-induced aggregation 
improved by 80 (௅) 
% after addition of the 
highest concentration of 
adrenaline (p<0.001) 
(Figure 20B). Adrenaline 
supplementation increased 
AA-induced aggregation 
by 60 ௅ZLWKWKH
highest concentration 
(p<0.001).  
A 
B 
Figure 20. Effect of adrenaline supplementation
(resulting plasma concentration) on ADP-induced
aggregation in blood samples from patients on dual
antiplatelet therapy with acetylsalicylic acid and
ticagrelor (n=10) (A) and pooled data from all
aggregation experiments (n=30) (B). Median and
interquartile range. Outliers are presented as
dots.***p<0.001, **p<0.01. 
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Effect of adrenaline alone or combined with platelets on 
platelet aggregation 
Supplementation with apheresis platelet concentrate did not increase ADP-
induced aggregation significantly (p=0.57) while it significantly increased 
AA-induced aggregation (p=0.007). Compared to samples supplemented with 
platelet concentrate, ADP-induced aggregation was higher while AA-induced 
aggregation was lower after adrenaline (770 nM) supplementation alone 
(p=0.005 and p=0.007, respectively). The combination of adrenaline and 
platelet concentrate increased both ADP- and AA-induced aggregation more 
than platelet concentrate alone (p=0.005 and p=0.007, respectively).  
Effect of adrenaline alone or combined with ADP on 
platelet aggregation and activation 
Supplementation with adrenaline alone (770 nM) increased platelet 
aggregation and activation compared to samples with no added agonist 
(Figure 21A and 21B). Supplementation with ADP alone increased 
aggregation and activation more than adrenaline alone. The combination of 
adrenaline and ADP increased aggregation more than either substance alone. 
The combination also resulted in the highest activation response. 
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A 
B 
Figure 21. Effects of adrenaline (Adr) (resulting plasma
concentration 770 nM) and/or ADP on platelet aggregation
(A) (n=10) and activation (PAC-1 binding to activated
fibrinogen receptor) (B) (n=10) in blood samples from
patients on dual antiplatelet therapy with acetylsalicylic
acid and ticagrelor. Median and interquartile range.
Extreme points are indicated by the symbol ×. **p<0.01,
*p<0.05. 
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4.3 Adrenaline infusion in ticagrelor-treated 
subjects (Study III) 
Infusion of adrenaline after ticagrelor administration increased the systolic 
blood pressure at infusion rates of 0.05‒0.15 µg/kg/min from 137 (136−141) 
mmHg to 160 (147−175) mmHg (p=0.007) at 0.10 µg/kg/min and heart rate 
at all infusion rates from 61 (54−68) beats/min to 86 (72−87) beats/min 
(p=0.015) at 0.15 µg/kg/min. In addition, adrenaline plasma concentration 
increased at all infusion rates from 0.25 (0.20‒0.40) to 14.28 (14.13‒16.82) 
nM (p=0.008) at 0.15 µg/kg/min. In contrast, infusion of adrenaline 
decreased the diastolic blood pressure and MAP at all infusion rates. 
Injection of metoprolol concomitantly with adrenaline infusion did not 
significantly change blood pressure or heart rate compared to the same 
infusion rate of adrenaline alone.  
Effect on platelet aggregation and activation 
After ticagrelor administration, the ADP- (Figure 22A), AA-, and TRAP-
induced aggregation decreased (p=0.005, p=0.005, and p=0.007, 
respectively). Following infusion of adrenaline, the ADP-induced 
aggregation improved without obvious dose-response; from median 17 (14‒
31) U to 25 (21‒34) U (p=0.012) at 0.10 µg/kg/min (Figure 22A). Seven 
study participants had an ADP-induced aggregation of <22 U after ticagrelor 
administration. In six of these, the ADP-induced aggregation increased to 
>22 U with infusion of adrenaline. AA- and TRAP-induced aggregation 
improved with adrenaline infusion rates of 0.05‒0.15 µg/kg/min. Injection of 
metoprolol concomitantly with adrenaline infusion did not significantly 
influence the ADP- or TRAP-induced aggregation in the presence of 
ticagrelor, compared to the same infusion rate of adrenaline alone (p=0.18 
and p=0.68 respectively) while AA-induced aggregation significantly 
increased with the combination (p=0.011).  
Ticagrelor administration significantly decreased ADP-induced PAC-1 
binding (p=0.012) (Figure 22B) and P-selectin expression (p=0.017) 
compared to baseline. Adrenaline infusion significantly increased both ADP-
induced PAC-1 binding (Figure 22B) and P-selectin expression. Injection of 
metoprolol concomitantly with adrenaline infusion significantly reduced 
ADP-induced PAC-1 binding compared to the same infusion rate of 
adrenaline alone (p=0.028) (Figure 22B) while the combination did not 
significantly change P-selectin expression (p=0.24). 
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Figure 22. The effect of ticagrelor, adrenaline (Adr)
infusion (0.01, 0.05, 0.10, and 0.15 μg/kg/min) and
metoprolol (5 mg) on ADP-induced platelet aggregation (A)
(n=10) and activation (PAC-1 binding to activated
fibrinogen receptor) (B) (n=8) in healthy volunteers.
Median and interquartile range. Outliers are presented as
dots and extreme points are indicated by the symbol ×.
**p<0.01, *p<0.05. 
A 
B 
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Effect on clot formation 
Ticagrelor administration did not significantly influence clot formation 
parameters (clotting time: Friedman test p=0.26, clot formation time: p=0.33, 
maximum clot firmness: p=0.076). Infusion of adrenaline did not 
significantly influence clotting time (Friedman test p=0.26) while the clot 
formation time reduced from 97 (89−110) s to 83 (76−90) s (p=0.008) at 0.15 
µg/kg/min and maximum clot firmness increased from 59 (57−60) mm to 62 
(61−64) mm (p=0.007) at 0.15 µg/kg/min. Injection of metoprolol combined 
with adrenaline infusion did not significantly change clot formation time or 
maximum clot firmness compared to the same infusion rate of adrenaline 
alone (p=0.18 and p=0.58, respectively). 
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4.4 Noradrenaline infusion in CABG patients 
(Study IV) 
Comparing the two randomization groups (noradrenaline and control), there 
were no significant differences 10 minutes before anesthesia in MAP, 
hemoglobin concentration, hematocrit, fibrinogen concentration, platelet 
aggregation, or clot formation.  
Dose of noradrenaline 
Patients in the noradrenaline group received a noradrenaline dose of median 
0.09 (range 0‒26) µg/kg/min at 50 minutes after anesthesia induction. One 
patient without noradrenaline infusion at 50 minutes received noradrenaline 
up to 40 minutes after anesthesia induction. Four patients in the control group 
had a noradrenaline infusion at a rate of 0.03‒0.12 µg/kg/min at 50 minutes 
after anesthesia induction.  
Effect on mean arterial pressure 
MAP did not significantly change between the two time-points in the 
noradrenaline group (p=0.31) while it significantly decreased in the control 
group (p=0.002). There was a significant difference in the change in MAP 
between the two groups; 3 (−3‒9) mmHg in the noradrenaline group 
compared to −35 (−40‒[−27]) mmHg in the control group (p<0.001). 
Effect on platelet aggregation  
In the noradrenaline group, ADP-induced aggregation significantly increased 
from 71 (53‒94) U at 10 minutes before anesthesia to 87 (70‒103) U 
(p=0.023) at 50 minutes after anesthesia induction. In contrast, ADP-induced 
aggregation significantly decreased between the two time-points, from 85 
(67‒90) U to 72 (64‒80) U (p=0.028), in the control group. The change in 
ADP-induced aggregation significantly differed between the groups 
(p=0.002) (Figure 23). The AA- and TRAP-induced aggregation did not 
significantly change in either group between the two time-points (p=0.27 and 
p=0.12, respectively for noradrenaline; p=0.12 and p=0.61, respectively for 
control). However, the change in AA-induced aggregation was significantly 
different between the groups (p=0.046) (Figure 23). There was no significant 
difference in the change in TRAP-induced aggregation between the groups 
(p=0.12) (Figure 23). 
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The effect of an increase of 0.01 μg/kg/min in noradrenaline infusion rate (up 
to 0.13 μg/kg/min) on the changes in ADP- and AA-induced aggregation 
between the two time-points ZHUH VLJQLILFDQW ¨/60   &, ௅
4.30) (p=0.003) for ADP (Figure 24A) DQG¨/60&,௅
(p=0.001) for AA (Figure 24B). Thus the mean effect of each 0.01 increase in 
noradrenaline infusion rate on the change in ADP- and AA-induced 
aggregation was +2.68 U and +1.79 U, respectively. When the infusion rate 
was >0.13 μg/kg/min, there was no significant effect. Furthermore, no 
significant effect of noradrenaline infusion rate on the change in TRAP-
induced aggregation was observed. 
Effect on clot formation 
A significant increase in INTEM maximum clot firmness in the noradrenaline 
group (p=0.009) was observed while no significant difference was observed 
in the control group (p=0.89). Also, a significant difference in the change in 
INTEM maximum clot firmness between the groups was observed (p=0.008). 
There was no significant change in FIBTEM maximum clot firmness in the 
noradrenaline group between the two time-points (p=0.12) while it 
significantly decreased in the control group (p=0.047). No other significant 
differences in clot formation parameters were observed.  
Figure 23. Change in ADP-, arachidonic acid (AA)-, and TRAP-induced
aggregation between samples collected at 10 minutes before and 50
minutes after anesthesia induction in cardiac surgery patients
randomized to either maintenance of pre-induction mean arterial
pressure by noradrenaline infusion (n=12) or standard treatment
(control) (n=12). Median and interquartile range. **p<0.01, *p<0.05. 
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A 
B 
Figure 24. Effect of the infusion rate of noradrenaline on the change in
ADP- (A) and arachidonic acid (AA)- (B) induced platelet aggregation
between the two sampling time-points in cardiac surgery patients
randomized to maintenance of pre-induction mean arterial pressure by
noradrenaline infusion (black circles) (n=12) or standard treatment
(control) (white circles) (n=12). Regression models with natural cubic
splines (black lines) were used. The spline functions were simplified
into piecewise linear functions (dotted lines) with a breaking point set
at 0.13 μg/kg/min. Difference in Least Squares Means ¨/60 ZLWK
95% Confidence Intervals (CI) are presented per 0.01 μg/kg/min
increase in the infusion rate. 
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5 DISCUSSION 
The main findings in this thesis were; IPU concentrates maintained a better 
platelet function compared to buffy-coat platelet concentrates during storage 
while apheresis platelet concentrates had a better maintained platelet function 
throughout the storage period (Study I); Adrenaline improved both ADP-
induced platelet aggregation and activation in the presence of ticagrelor in 
vitro (Study II) and in vivo (Study III) while supplementation with apheresis 
platelet concentrate did not enhance ADP-induced platelet aggregation in 
vitro (Study II); Adrenaline infusion also improved clot formation in the 
presence of ticagrelor in vivo (Study III) while intraoperative infusion of 
noradrenaline improved ADP-induced platelet aggregation and clot formation 
in cardiac surgery patients (Study IV).  
Platelet concentrates during storage (Study I) 
There were significant differences in platelet storage lesion markers between 
IPU, buffy-coat and apheresis platelet concentrates during storage. This may 
be explained by the differences in collection and preparation method, storage 
medium, and plasma carryover which are known to affect the storage lesion 
of platelet concentrates [99]. The different number of centrifugation steps 
required for the preparation of IPU and apheresis concentrates (single step), 
and buffy-coat platelet concentrates (two steps) may affect platelet activation 
and aggregation. Furthermore, IPU and buffy-coat platelet concentrates were 
stored in the platelet additive solutions SSP+ and SSP, respectively. The 
additional magnesium and potassium only present in SSP+ can reduce 
platelet activation [100, 101] while the additional phosphate acts as a buffer. 
Lastly, the plasma carryover (40% in IPU, 20% in buffy-coat, and 100% in 
apheresis platelet concentrates) may affect platelet activation. Using plasma 
as storage medium has previously been shown to cause a lower activation of 
buffy-coat platelets compared to using SSP [102]. However, it is beneficial to 
have a lower plasma carryover as transfusions of plasma may cause adverse 
transfusion reactions [103]. 
Platelets in apheresis platelet concentrates had a better platelet function 
compared to platelets in IPU concentrates during storage. To our knowledge, 
no previous studies have compared the new IPU concentrates to apheresis 
platelet concentrates. Comparisons between IPU concentrates and buffy-coat 
concentrates have previously been conducted. In a study by Johnson and 
colleagues, IPU concentrates (Reveos system prototype) were compared to 
buffy-coat platelet concentrates (Optipress system) [104]. The results of that 
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study are not in line with the results of our study. Johnson and colleagues 
found; no significant difference in pH and glucose while lactate concentration 
was significantly different, that more platelets in IPU concentrates were 
activated throughout the storage period, and that ADP-induced aggregation 
was higher while collagen-induced aggregation was lower in IPU platelet 
concentrates. The differences in results of metabolic parameters and platelet 
activation between the studies may be explained by the fact that the storage 
medium differed between our IPU and buffy-coat platelet concentrates (SSP+ 
and SSP, respectively) while SSP+ was used for both types of preparations in 
the other study. The discrepancy in aggregation results between the two 
studies may be due to differences in aggregometry methods, agonist 
concentrations, buffy-coat collection methods and storage medium. 
Platelet storage lesion is associated with the storage temperature. The platelet 
concentrates at our hospital are stored at 22°C. Cold-storage (2‒6°C) of 
platelet concentrates results in a lower metabolic rate and a better maintained 
platelet aggregation response compared to platelet concentrates stored at 
room temperature [105, 106]. However in vivo, transfusion of cold-stored 
platelets resulted in quicker clearance of the transfused platelets from the 
circulation compared to platelets stored at room temperature [107]. Cold-
stored platelets may be of use in patients with ongoing bleeding as a rapidly 
improved platelet function to stop bleeding might be more important than the 
need for platelets with a longer circulation time. 
Effects of adrenaline on platelet function (Studies II and III) 
Supplementation with adrenaline to blood samples from patients on DAPT 
with ASA and ticagrelor, and infusion of adrenaline to ticagrelor-treated 
healthy volunteers increased ADP-induced platelet activation and 
aggregation, and AA-induced aggregation (Studies II and III). The ADP-
induced aggregation reached median levels of approximately 25 U both in 
vitro (resulting adrenaline plasma concentration 770 nM) and in vivo (9.95 
nM at 0.10 µg/kg/min). Thus in both studies, adrenaline improved ADP-
induced platelet aggregation to reach above a previously suggested cut-off 
level of 22 U for when CABG may be performed without an increased 
bleeding risk [52, 53]. This suggests that adrenaline infusion could 
potentially be used to prevent perioperative bleeding complications in 
patients with ongoing or recently discontinued treatment with ASA and 
ticagrelor.  
A potentiating effect of adrenaline on ADP-induced aggregation has 
previously been observed in blood samples from clopidogrel-treated patients 
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[66]. Also, a study on platelet-rich plasma from healthy subjects where 
ticagrelor was added in vitro showed that ADP-induced aggregation 
improved after adrenaline supplementation (1 µM) [67]. The in vivo effect of 
adrenaline on platelet function has also been studied. Infusion of adrenaline 
(0.07 µg/kg/min) was shown to improve platelet aggregation in healthy 
volunteers without antiplatelet therapy in two studies [76, 108] while there 
was no difference in ADP-induced aggregation after infusion of adrenaline 
(0.06 µg/kg/min) or saline only in another study [109]. The difference in 
methods used for analyzing platelet aggregation may be a reason for the 
conflicting results. To our knowledge, no studies have investigated platelet 
function after adrenaline supplementation to blood samples from ticagrelor-
treated ACS patients or during adrenaline infusion in ticagrelor-treated 
subjects. 
As is evident in Studies II and III, a higher adrenaline plasma concentration 
was required for potentiation of ADP-induced aggregation in vitro (153 and 
770 nM) compared to measured plasma concentrations after infusion in vivo 
(14 nM for the highest rate). Also, the effect of adrenaline supplementation 
was concentration-dependent in vitro (Study II) while no evident dose-
dependent effect of adrenaline was observed in vivo (Study III). Adrenaline 
infusion at rates of 0.05‒0.15 µg/kg/min improved ADP-induced aggregation 
to nearly the same degree. A possible explanation could be that the α2A-
receptors become desensitized with a continuous infusion. The affinity of 
adrenaline for α2A-receptors has previously been shown to decrease after a 2-
hour infusion of adrenaline (0.05 µg/kg/min) [110].  
The potentiation of ADP-induced aggregation by adrenaline may be 
explained by its effect on platelet signaling pathways. Adrenaline can bind to 
platelet α2A-receptors which activates a pathway that mimics the P2Y12-
mediated pathway [31, 68, 72] which ticagrelor inhibits. An alternative 
explanation to the improvement in platelet aggregation observed in vivo 
(Study III) is that adrenaline infusion increases the platelet concentration. In a 
previous study, adrenaline infusion decreased the splenic platelet pool size 
and increased venous platelet concentration [111]. We did not measure 
platelet concentration during the infusion of adrenaline and can thus not with 
certainty determine the cause of the improved platelet aggregation. At the 
screening visit, the platelet concentration was in the normal range for all 
participants (ranged between 180‒307 × 109/L). Only a platelet concentration 
of ≤100 × 109/L has previously been shown to influence impedance 
aggregometry results [112].  
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Adrenaline is used to increase blood pressure during and after CPB if patients 
undergoing cardiac surgery become hypotensive. As adrenaline increases 
heart rate and systolic blood pressure, an agent that can counteract the 
increase may be needed if adrenaline is used as a platelet function-enhancing 
agent in patients on DAPT. For this purpose, we investigated the effect of 
metoprolol (β1-selective blocker) administration during adrenaline infusion. 
The results indicate that metoprolol does not negatively influence 
adrenaline’s effect on platelet function (except lower ADP-induced PAC-1 
binding). Thus a β1-selective blocker may be used in combination with 
adrenaline to prevent an increased blood pressure without impairing 
adrenaline’s effect on platelets.  
In Study II, supplementation with apheresis platelet concentrate alone did not 
significantly improve ADP-induced aggregation while it improved AA-
induced aggregation. This is in agreement with previous studies [49-51]. This 
shows that platelet transfusion may be used to target the ASA-induced 
platelet inhibition in patients on DAPT. 
Adrenaline infusion also improved clot formation (Study III). Although the 
inhibiting effect of ticagrelor cannot be identified using only viscoelastic 
coagulations tests, a positive effect of adrenaline infusion was still observed 
(shortening of clot formation time and increased maximum clot firmness). 
This is most probably due to the effect of adrenaline on platelets, but also an 
increase of platelet concentration [111] and/or effects on vWF and factor VIII 
coagulant activity [113] may contribute. A positive effect of adrenaline 
infusion on coagulation parameters has previously been observed. In a 
randomized trial, perioperative infusion of low dose adrenaline (0.05 
µg/kg/min) in combination with the anifibrinolytic agent tranexamic acid 
during total hip arthroplasty improved early postoperative coagulation 
parameters compared to a placebo group [79]. 
Effect of intraoperative noradrenaline infusion (Study IV) 
Noradrenaline infusion resulted in improvements in ADP- and AA-induced 
aggregation that were significantly different from the changes observed in the 
control group. In addition, INTEM maximum clot firmness increased in the 
noradrenaline group. This strongly indicates that intraoperative noradrenaline 
infusion improves platelet aggregation and clot stability.  
Noradrenaline is the adrenergic agent used for maintenance of blood pressure 
during cardiac surgery at our institution. No previous studies have assessed 
platelet function during noradrenaline infusion in patients undergoing 
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surgery. However, in a previous study on healthy volunteers, noradrenaline 
infusion (0.03 and 0.14 µg/kg/min) improved platelet aggregation [77]. An 
improvement was also observed in another study on healthy volunteers and 
hypertensive patients after noradrenaline infusion (0.10 µg/kg/min) [78]. In 
the present study, noradrenaline infusion improved ADP-induced aggregation 
and the effect of the infusion rate on the changes in ADP- and AA-induced 
aggregation was significant up to 0.13 µg/kg/min. Higher infusion rates did 
not significantly affect the change in platelet aggregation which corresponds 
to the results from Study III where there was no obvious dose-dependency for 
ADP-induced aggregation over an adrenaline infusion rate of 0.05 µg/kg/min. 
The improvement observed after noradrenaline infusion could be because 
noradrenaline also binds to α-receptors on platelets and binding can result in 
aggregation, but it is not as potent as adrenaline [63-65]. Another explanation 
for the improvement is that the platelet concentration may increase during 
noradrenaline infusion [77]. We only measured platelet concentration 
preoperatively and can therefore not with certainty determine if the 
improvement is due the effect of noradrenaline on platelet aggregation or on 
platelet concentration. However as previously discussed, only a platelet 
concentration of ≤100 × 109/L has previously been shown to influence 
impedance aggregometry results [112]. All patients had a platelet 
concentration within the normal range preoperatively (ranged between 163‒
388 × 109/L) and it is unlikely that the platelet concentration was ≤100 × 
109/L when the second measurement was conducted since the CPB had not 
yet been started. 
In a prospective randomized trial of patients undergoing open radical 
cystectomy, noradrenaline infusion (first 0.033 µg/kg/min then maintenance 
of MAP 60‒100 mmHg) in combination with a restrictive fluid regimen 
resulted in lower perioperative blood loss and red blood cell transfusion 
requirement compared to a control group [114]. In a study on cardiac surgery 
patients, noradrenaline infusion resulted in a higher hemoglobin 
concentration upon admission to the intensive care unit and lower frequency 
of perioperative blood transfusions compared to a historical control group 
[115]. However, the mechanism behind the effect of noradrenaline on 
hemostasis was not explored in these studies. Our results indicate that 
noradrenaline’s effect on platelet aggregation may contribute. 
Limitations and strengths of the studies 
There are some limitations of the studies. In Study I, we did not control for 
the differences in storage medium and plasma carryover between the three 
types of platelet concentrates. Thus, we cannot distinguish between the 
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effects of the different factors on platelet storage lesion. The aggregation 
analysis was performed with the same volume of platelet concentrate 
regardless of the platelet concentration as the concentration is not considered 
when giving the product to the patient. It may have affected the aggregation 
results although we only observed significant correlations between platelet 
concentration and TRAP-induced aggregation. Furthermore, impedance 
aggregometry is not yet established as a method for evaluating platelet 
function in platelet concentrates. It has however been used in previous studies 
[45, 116, 117]. 
In Study II, we only observed significant effects on platelet aggregation at the 
two highest adrenaline plasma concentrations tested. These plasma 
concentrations cannot be achieved in vivo by adrenaline infusion at doses that 
are clinically relevant [118]. Furthermore, the in vitro supplementation of 
adrenaline to blood samples does not take into account the effect of the 
vascular endothelium and blood flow on primary hemostasis. In Study III, no 
women were included to avoid effect of the hormone cycle on platelet 
function [96]. This is a limitation as the findings may not apply to the female 
population. Furthermore, ticagrelor, which is almost solely given in 
combination with ASA, was in our study given as monotherapy to avoid a 
further increased bleeding risk for the healthy volunteer. Lastly, we did not 
have a control group receiving placebo to determine the effect of other 
variables in the study setup.  
Study IV was a substudy of a randomized trial with another objective and 
was thus not powered for evaluation of hemostatic variables, postoperative 
bleeding, transfusions or outcomes. In addition, the sample size was small. 
Lastly, a limitation with both Studies III and IV was that platelet 
concentration was not measured during or after adrenaline or noradrenaline 
infusion.  
Strengths of Study I include the study design which enabled us to compare 
the actual platelet products given to patients at our hospital. In addition, we 
were able to follow each individual platelet concentrate for 7 days. We also 
used multiple methods of assessing platelet storage lesion.  
Strengths of Study II include that blood samples with no added agents 
(baseline) were used for the comparisons. In this way, the patients were their 
own control. In addition, both platelet activation and aggregation were 
evaluated yielding a more comprehensive picture of the effect of adrenaline 
on platelet function. 
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Strengths of Study III include the healthy volunteers being their own control. 
In addition, platelet activation and aggregation, and clot formation were 
studied yielding information about the effect of adrenaline on different 
aspects of hemostasis. We also evaluated five infusion rates of adrenaline as 
well as the combination of adrenaline and metoprolol under controlled 
conditions.  
Strengths of Study IV include the surgical setting and the randomization 
aspect which allowed for comparisons between a treatment group and a 
control group of cardiac surgery patients. In addition, both platelet 
aggregation and clot formation were evaluated.  
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6 CONCLUSIONS 
1. IPU, buffy-coat and apheresis platelet concentrates 
significantly differed in platelet storage lesion markers.  The 
new IPU concentrates are at least comparable to buffy-coat 
platelet concentrates in terms of quality markers during 
storage. 
 
2. Adrenaline supplementation to blood samples from patients 
treated with ASA and ticagrelor improved ADP- and AA-
induced platelet aggregation and ADP-induced platelet 
activation. 
 
3. Supplementation with apheresis platelet concentrate to blood 
samples from patients treated with ASA and ticagrelor 
improved AA-induced platelet aggregation while the 
combination of adrenaline and platelet concentrate improved 
both ADP- and AA-induced aggregation.  
 
4. Adrenaline infusion at clinically relevant doses improved 
platelet aggregation, activation and clot formation in 
ticagrelor-treated healthy volunteers.  
 
5. Intraoperative infusion of clinically relevant doses of 
noradrenaline in ASA-treated cardiac surgery patients 
improved platelet aggregation and clot formation. 
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7 FUTURE PERSPECTIVES 
Treatment or prevention strategies of perioperative bleeding during cardiac 
surgery, especially in patients with ongoing or recently discontinued 
treatment with a P2Y12 antagonist, are needed. Current strategies include 
transfusion of platelet concentrates. We have compared platelet storage lesion 
in the newly introduced IPU concentrates with buffy-coat and apheresis 
platelet concentrates prepared according to local routines. The preparation of 
platelet concentrates differs between hospitals. Studies investigating the 
optimal preparation and storage conditions need to be conducted. With our 
study design, we could not distinguish the effect of the different factors on 
platelet storage lesion. To investigate the effect of the collection methods, 
platelet concentrates prepared with the same storage medium and plasma 
carryover need to be evaluated. Furthermore, the in vivo effect of transfusion 
of the different platelet concentrates on hemostasis should be investigated.  
As a possible new prevention strategy, adrenergic agents were tested in the 
next studies. We found that adrenaline improved platelet aggregation and 
activation in the presence of ticagrelor both in vitro and in vivo as well as clot 
formation in vivo. Furthermore, we found that noradrenaline infusion 
improved platelet aggregation and clot formation in ASA-treated cardiac 
surgery patients. To confirm our findings and to evaluate if the effects are 
sufficient to improve perioperative hemostasis, larger studies investigating 
the effect of adrenergic agents in cardiac surgery patients with ongoing or 
recently discontinued DAPT should be conducted. Such a study can also 
investigate if an optimal dose of adrenaline can be determined for the 
enhancement of ADP-induced platelet reactivity. 
Adrenaline supplementation and infusion improved ADP-induced platelet 
aggregation in ticagrelor-treated samples however; the aggregation did not 
reach the normal levels observed before antiplatelet therapy is initiated. For 
the purpose of restoring ADP-induced aggregation, an antidote to ticagrelor 
has been developed and is currently evaluated. The antidote was shown to 
restore ADP-induced aggregation in ticagrelor-treated human platelet-rich 
plasma and mice [119]. It has also more recently been tested in pigs treated 
with ASA and supra-therapeutic level of ticagrelor during ongoing bleeding 
[120]. The antidote cleared free ticagrelor and its active metabolite in plasma 
within 5 minutes and gradually restored ADP-induced platelet aggregation. 
However, it did not significantly reduce blood loss. Studies in humans will 
reveal if the antidote may be used in the future for prevention and treatment 
of bleeding complications in ticagrelor-treated patients. 
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